146 related articles for article (PubMed ID: 17873184)
1. Transition from IV to subcutaneous prostacyclin: premature withdrawal?
Shapiro S; Hill NS
Chest; 2007 Sep; 132(3):741-3. PubMed ID: 17873184
[No Abstract] [Full Text] [Related]
2. [Transition from intravenous to subcutaneous prostacyclin in pulmonary hypertension].
Escribano Subías P; Cea-Calvo L; Tello de Menesses R; Gómez Sánchez MA; Delgado Jiménez JF; Sáenz de la Calzada C
Rev Esp Cardiol; 2003 Aug; 56(8):818-21. PubMed ID: 12892628
[TBL] [Abstract][Full Text] [Related]
3. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.
Rubenfire M; McLaughlin VV; Allen RP; Elliott G; Park MH; Wade M; Schilz R
Chest; 2007 Sep; 132(3):757-63. PubMed ID: 17400684
[TBL] [Abstract][Full Text] [Related]
4. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
[TBL] [Abstract][Full Text] [Related]
5. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.
McLaughlin VV; Palevsky HI
Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307
[TBL] [Abstract][Full Text] [Related]
6. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
Suleman N; Frost AE
Chest; 2004 Sep; 126(3):808-15. PubMed ID: 15364760
[TBL] [Abstract][Full Text] [Related]
7. Impact of switching from epoprostenol to IV treprostinil on treatment satisfaction and quality of life in patients with pulmonary hypertension.
Minai OA; Parambil J; Dweik RA; Davila GH; Peterson L; Rollins KD; Chen H
Respir Med; 2013 Mar; 107(3):458-65. PubMed ID: 23266038
[TBL] [Abstract][Full Text] [Related]
8. Treprostinil for the treatment of pulmonary hypertension.
Skoro-Sajer N; Lang I
Expert Opin Pharmacother; 2008 Jun; 9(8):1415-20. PubMed ID: 18473715
[TBL] [Abstract][Full Text] [Related]
9. Infections by gram-negative bacilli in patients with pulmonary arterial hypertension treated with intravenous prostacyclin.
Gómez Sánchez MA
Arch Bronconeumol; 2013 Mar; 49(3):128-9. PubMed ID: 23127721
[No Abstract] [Full Text] [Related]
10. Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease.
Bakst AE; Gaine SP; Rubin LJ
Chest; 1999 Oct; 116(4):1127-9. PubMed ID: 10531185
[TBL] [Abstract][Full Text] [Related]
11. Prostacyclin withdrawal in pulmonary hypertension #264.
Bartlett C; Landzaat L;
J Palliat Med; 2013 Feb; 16(2):204-5. PubMed ID: 23336356
[No Abstract] [Full Text] [Related]
12. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
LeVarge BL; Channick RN
Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
[TBL] [Abstract][Full Text] [Related]
13. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension.
Vachiéry JL; Hill N; Zwicke D; Barst R; Blackburn S; Naeije R
Chest; 2002 May; 121(5):1561-5. PubMed ID: 12006444
[TBL] [Abstract][Full Text] [Related]
14. Treprostinil for pulmonary hypertension.
Vachiéry JL; Naeije R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
[TBL] [Abstract][Full Text] [Related]
15. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
16. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension.
Nagaya N; Sasaki N; Ando M; Ogino H; Sakamaki F; Kyotani S; Nakanishi N
Chest; 2003 Feb; 123(2):338-43. PubMed ID: 12576349
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis.
Humbert M; Maître S; Capron F; Rain B; Musset D; Simonneau G
Am J Respir Crit Care Med; 1998 May; 157(5 Pt 1):1681-5. PubMed ID: 9603154
[TBL] [Abstract][Full Text] [Related]
18. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.
Ivy DD; Claussen L; Doran A
Am J Cardiol; 2007 Mar; 99(5):696-8. PubMed ID: 17317374
[TBL] [Abstract][Full Text] [Related]
19. Rapid Switch From Subcutaneous to Intravenous Treprostinil in Precapillary Pulmonary Hypertension by Pump Implantation.
Steringer-Mascherbauer R; Maria L; Reinhold F; Elisabeth S; Charlotte H; Dagmar E; Uwe F; Josef A
J Cardiovasc Pharmacol; 2021 Jan; 77(1):38-42. PubMed ID: 33079830
[TBL] [Abstract][Full Text] [Related]
20. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
